Tecovirimat Use under Expanded Access to Treat Mpox in the United States, 2022–2023
Tecovirimat was used extensively. The returned EA-IND data suggest that life-threatening or protracted infections occurred in persons who were severely immunocompromised. SAEs were not commonly reported. The EA-IND data are not definitive; controlled clinical trial data are essential to elucidating if and how tecovirimat should be used.
Authors
- Riad Elmor
- Agam K. Rao (ORCID: https://orcid.org/0000-0002-7231-555X)
- Patricia Yu
- Kalimah Muhammad
- Yon Yu
Institutions
- Booz Allen Hamilton (United States) (US)
- Cherokee Nation (US)
- National Center for Emerging and Zoonotic Infectious Diseases (US)
Publication Details
- Journal
- NEJM Evidence
- Published
- 2024-09-13
- DOI
- https://doi.org/10.1056/evidoa2400189
- Citations
- 35
- Primary Topic
- Poxvirus research and outbreaks
- Type
- article
- Field-Weighted Citation Impact
- 10.28
Funders
- U.S. Department of Health and Human Services
- Centers for Disease Control and Prevention